DAB486IL-2 data

By WIR Staff | Sep 7, 1993 | 7:00 AM GMT

SRGN published data from separate Phase I trials of DAB486IL-2 in chemotherapy-resistant cancer patients. Data from

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

Article Purchase

This article may not be distributed to non-subscribers

More Info >PURCHASE